Demant A/S · OMXCOP:DEMANT
Demant A/S — Q3 2026 Earnings Presentation
16 slides from Demant A/S's earnings presentation, Nov 4, 2026
Slide 1: Interim Management Statement Q3 2026
Interim Management Statement Q3 2026 4 November 2026 Søren Nielsen, President & CEO René Schneider, CFO Investor Relations 1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements that reflect Demant’s current expectations regarding future events and financial performance. Forward-looking statements are statements other than historical facts and include, without limitation, statements that may pr
Slide 3: Capital Markets Day
Capital Markets Day DATE Tuesday, 24 November 2026 LOCATION Demant headquarters, Copenhagen, Denmark Reach out to the IR team SIGN UP - Peter Pudselykke – pepu@demant.com - Christine Ø. Arnild - cirn@demant.com 3
Slide 4: Agenda
Agenda Business highlights and key financial takeaways Business area review Outlook for 2026 Q&A 4
Slide 5: Business highlights Q3 2026
Business highlights Q3 2026 The Group delivered revenue growth of 21%, fuelled by very 1 strong organic growth of 17% in Hearing Aids and supported by a hearing aid market that grew by 7% in value in Q3 As announced on 9 October, we upgraded our financial outlook for 2026 and now expect organic grow
Slide 6: Key financial takeaways for Q3 2026
Key financial takeaways for Q3 2026 Very strong Group organic growth of 11%, with acquisitions 11% contributing 10%, totalling 21% reported growth Revenue Growth Business area Gross margin increased significantly year-over-year and was (DKK million) Q3 26 Q3 25 Org. Acq. LCY FX Rep. ahead of our exp
Slide 7: Business area review
Business area review 7
Slide 8: The hearing aid market in Q3 2026
The hearing aid market in Q3 2026 Estimated market growth in Q3 2026: We estimate that the total hearing aid market grew by around 7% in 2026 value in Q3 Unit growth1 Q1 Q2 Q3 YTD We estimate that the global hearing aid market saw unit growth of 6% Europe 2% 2% 8% 4% in Q3 compared to the same perio
Slide 9: Hearing Aids in Q3 2026
Hearing Aids in Q3 2026 Very strong growth driven by the launch of Oticon Reveal Comments Revenue and growth Organic growth in external revenue of 17%, significantly above Revenue Growth expectations despite slightly tougher comparative figures than (DKK million) Q3 26 Q3 25 Org. Acq. LCY FX Rep. in
Slide 10: Hearing Care in Q3 2026
Hearing Care in Q3 2026 Solid organic growth and a significant contribution from KIND Comments Revenue and growth Broad-based organic growth of 6%, slightly ahead of expectations, Revenue Growth driven by both unit growth and a positive ASP development (DKK million) Q3 26 Q3 25 Org. Acq. LCY FX Rep.
Slide 11: Diagnostics in Q3 2026
Diagnostics in Q3 2026 Organic growth in line with expectations Comments Revenue and growth Organic growth of 4%, which is in line with expectations and Revenue Growth slightly above the estimated market growth rate (DKK million) Q3 26 Q3 25 Org. Acq. LCY FX Rep. Growth was driven both by our servic
Slide 12: Outlook for 2026
Outlook for 2026 12
Slide 13: 2026 outlook assumptions
2026 outlook assumptions The financial outlook is based on a competitive environment, with several competitors launching products in H2, and on a number of additional key assumptions as described below: Market Demant Following the positive development in the hearing aid market in Q3, In February 202
Slide 14: Outlook for 2026
Outlook for 2026 The financial outlook for 2026 was upgraded on 9 October and is summarised below Metric Outlook Organic growth 7-8% EBIT before special items DKK 4,700-5,000 million Share buybacks At least DKK 3 billion from Q4 2026 to end of 2027 For modelling purposes, we provide further assumpti
Slide 15: Q&A
Q&A ,
Slide 16: IR contacts
IR contacts Roadshows and conferences: 05 Nov London (UBS) 05 Nov Paris (SEB) Peter Pudselykke 06 Nov Copenhagen (ABG Sundal Collier) Head of Investor Relations 10 Nov London (UBS Conference) Email: pepu@demant.com Tel: +45 3917 7300 24 Nov Capital Markets Day Mob: +45 2830 7638 26 Nov Copenhagen (D